Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)
EUROPACE, vol.19, no.11, pp.1757-1777, 2017 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Atrial fibrillation, Valvular heart disease, Mitral stenosis, Mechanical prosthetic heart valves, Thrombo-embolism, Stroke, Stroke prevention, Anticoagulation, Vitamin K antagonists, Non-vitamin K antagonist oral anticoagulants, Pregnancy, AORTIC-VALVE-REPLACEMENT, LOW-DOSE ASPIRIN, ORAL ANTICOAGULANT-THERAPY, LONG-TERM WARFARIN, APPENDAGE CLOSURE, TASK-FORCE, STROKE PREVENTION, EXPERT CONSENSUS, DECISION-MAKING, MITRAL-VALVE
Eskisehir Osmangazi University Affiliated:
Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with valvular heart disease (VHD) is also common. However, management strategies for this group of patients have been less informed by randomized trials, which have largely focused on 'non-valvular AF' patients.